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DaCan Chen2,4 and Charlie C. Xue1,4*Abstract
Background: Atopic eczema or atopic dermatitis is a chronic inflammatory skin disease. Current conventional
medical treatment for moderate and severe atopic eczema is not satisfactory. There is promising evidence derived
from randomised clinical trials to support the clinical use of Chinese herbal medicine in the management of atopic
eczema. However, the available evidence is compromised by the high risk of bias associated with most of the
included trials. Therefore, well-designed and adequately powered randomised clinical trials are needed. The primary
aim of this trial is to evaluate the efficacy and safety of oral ingestion of an oral Chinese herbal formula (Pei Tu Qing
Xin granules; PTQX) in children aged between 6 and 16 years with moderate to severe atopic eczema.
Methods/Design: We have designed a randomised, double-blind, placebo-controlled, two-arm, parallel clinical trial
with 12 weeks of treatment and a 4-week follow-up period. A pilot study with 30 participants will be conducted
at the RMIT University in Australia to determine the feasibility of the full-scale randomised clinical trial (N = 124).
Eczema Area and Severity Index score will be the primary outcome. Secondary outcome measures include change
in symptoms using the Patient-Oriented Eczema Measure, the Children’s Dermatology Life Quality Index and the
use of concomitant medicines. Safety parameters include report of adverse events and pathology tests during the
trial period.
Discussion: Key elements for conducting a high-quality randomised clinical trial have been addressed in this
protocol. Findings from the proposed trial will provide critical evidence regarding Chinese herbal medicine
treatment for atopic eczema.
Trial registration: Australian New Zealand Clinical Trials Registry Identifier: ACTRN12614001172695. Date of
Registration: 7 November 2014.
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Atopic eczema (AE) or atopic dermatitis is an inflamma-
tory skin disease characterised by redness of the skin,
scaling, swelling, accentuation of the hair follicles and
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creativecommons.org/publicdomain/zero/1.0/to severe itchiness [1]. The prevalence of AE worldwide
ranges from 1 % to 20 %. Nigeria, the United Kingdom
and New Zealand have the highest reported prevalences
[2]. A recent Australian prospective cohort study done
over the course of 40 years showed that childhood ec-
zema was strongly associated with the incidence and
persistence of adult atopic asthma, suggesting that early
treatment may reduce morbidity later in life [3].
Management of mild AE includes topical application
of corticosteroids and emollients, and refractory mo-
derate or severe AE is managed with systemic therapies,
including oral steroids or immunosuppressive drugsdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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methotrexate [4, 5]. Current conventional medical treat-
ment for moderate and severe AE is not satisfactory, as
long-term oral corticosteroid use can lead to adverse re-
actions such as suppression of the hypothalamic–pituit-
ary–adrenal axis, osteoporosis, aseptic necrosis of the
hip, hypertension, ocular changes and altered immune
function [6]. Side effects of immunosuppressive medi-
cations, in particular the risk of hepatosplenic T-cell
lymphomas associated with azathioprine, have raised
alert [7]. Therefore, many people with AE may choose to
use Chinese herbal medicine (CHM) for the treatment
of AE [8].
CHM has a long history of use, dating back to the sec-
ond century AD. Unlike conventional medicine, CHM
uses a composite of different botanical resources such as
barks, seeds, flowers, roots or mineral substances to cre-
ate a formula which is administered as decoctions, pills,
washes, lotions or ointments. There has been increasing
interest in evaluating the efficacy and safety of CHM for
AE. To determine the benefit of CHM for AE, we com-
pleted a Cochrane systematic review of CHM for AE in
2013 [9]. A total of 28 studies were included in the re-
view (2306 participants). There is evidence that CHM
has increasingly been used for the management of AE
since the publication of the first Cochrane systematic re-
view in this area in 2004. All included trials have pre-
sented the benefit of CHM was superior or equivalent to
its comparator. However, the promising effect claimed
by the trials’ investigators is compromised by the high
risk of bias within most of the included trials, and we
further suggested that well-designed, adequately pow-
ered randomised clinical trials (RCTs) are needed.
Trial objective
The primary objective of the present trial is to determine
the efficacy and safety of oral ingestion of an existing
oral Chinese herbal formula (Pei Tu Qing Xin granules;
PTQX) on symptom severity and improvement in
health-related quality of life (QoL) in children aged be-
tween 6 and 16 years with moderate to severe AE. We
will also assess the safety of PTQX for AE.
Methods/Design
The trial will be a 16-week, randomised, double-blind,
placebo-controlled, two-arm, parallel clinical trial. The
16-week trial includes 12 weeks of treatment with either
PTQX or placebo and a 4-week follow-up period.
Figure 1 outlines the process of the trial. A pilot study
(N = 30) will be conducted to inform a planned larger
RCT (N = 124). The study protocol was approved by
the Royal Melbourne Institute of Technology (RMIT)
University Human Research Ethics Committee (HREC),
filed with the Therapeutic Goods Administration (TGA)under the Clinical Trial Notification (CTN) scheme
(CTN file number: 2014/033590) and registered with the
Australian and New Zealand Clinical Trials Registry
(ANZCTR) (registration ID: ACTRN12614001172695;
dated 7 November 2014).
Randomisation
A block randomisation method will be employed with
balanced variable blocks. Equal numbers of participants
will receive the real treatment and the inert vehicle
(the placebo). Randomisation codes will be generated by
a computer program run by an independent statistician
who is not directly involved with the trial.
Blinding and allocation concealment
Neither the trial participants nor investigators will know
the participant allocation to receive real treatment or
placebo. The randomisation codes will be concealed in
individual opaque envelopes. Envelopes will be sequen-
tially numbered and opened only after the participant’s
unique identifier is written on the envelope. At the time
of randomization (visit 1, week 0), each participant will
randomly pick one sealed envelope from among the
group. The envelope will be opened by a CHM dispen-
ser, who will be a registered CHM practitioner or regis-
tered CHM dispenser. The trial medication (both PTQX
and placebo) will be prepackaged, and the appearance of
the packages will be identical. The randomisation code
will not be revealed to participants and personnel who
are involved in data entry and data analysis. An emer-
gency unblinding envelope with identical contents will
be prepared in case a serious adverse event occurs dur-
ing the treatment period. In case of a serious adverse
event where immediate cessation of trial medication is
required, the emergency unblinding envelope will be
opened for further investigation of the nature of the
event by the trial investigators.
Preparation and administration of the trial medications
The trial medications will be prepared by Jiangyin Tianjiang
Pharmaceutical Co. Ltd., a Good Manufacturing Practices–
certified CHM extract granules manufacturer. Quality
control and quality assurance, such as identification of
products and quality and safety testing, were conducted
by the manufacturer. The raw herbs were mixed, cooked
twice with water, filtered, concentrated, spray-dried
and mixed with sucralose and pearl powder (Margarita
powder) and finally forming granules (PTQX). They were
packaged in small sachets weighing 2 g each. A sample
batch of PTQX was tested for microorganisms and is de-
posited with the manufacturer for traceability. In addition,
a fingerprint profile of PTQX has been established by
using an ultra high-performance liquid chromatography–
high resolution mass spectrometry operated in multistage
Fig. 1 Flowchart of the trial process
Gu et al. Trials  (2015) 16:294 Page 3 of 6mode profiling method for further study of the active
compounds of the formula.
PTQX is modified from a CHM formula, Qing Xin Pei
Tu, which is based on the principle of treatment in
strengthening the spleen and eliminating the heart fire in
Chinese medicine, and most children with AE manifested
with deficiency of the spleen and heart fire [10, 11]. The
formula has been used in children with AE for many years
[10–12]. The formula is prepared as CHM granules with
extracts from nine Chinese medicinal substances, in-
cluding Rhizoma Atractylodis macrocephalae (Bai Zhu),
Radix Pseudostellariae (Tai Zi Shen), Rhizoma Dioscoreae
(Shan Yao), Semen Coicis (Yi Yi Ren), Rhizoma Imperatae
(Bai Mao Gen), Fructus Forsythiae (Lian Qiao), Radix
Glycyrrhizae (Gan Cao), Cortex Dictamni (Bai Xian Pi)
and Margarita (Zhen Zhu Feng). In CHM theory, Bai Zhu
has the function of strengthening the spleen, and Lian
Qiao can clear away the heart fire and remove toxins.These two herbs serve as sovereign (jun) herbs. Bai
Mao Gen is used to cool the blood and reduce swelling
by promoting diuresis. Tai Zi Shen, Yi Yi Ren and Shan
Yao have the function of strengthening the spleen and
eliminating dampness. These four substances act as
minister (chen) herbs to further enhance the effects of
the sovereign herbs. Zhen Zhu Feng calms the mind
and extinguishes the wind. Bai Xian Pi has the function
of clearing away heat, drying the dampness, expelling
the wind and easing itchiness. These two ingredients
work as assistant (zuo) role in the formula. Can Cao is
a guide (shi) herb, as it harmonises all ingredients of
the formula [13]. Evidence derived from preclinical re-
search have shown that Atractylodis macrocephalae
and Semen Coicis could improve the immune function
by increasing interleukin (IL)-1 or IL-2, and Fructus
Forsythiae and Radix Glycyrrhizae have anti-inflammatory
action [14].
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for 6–7-year-old subjects and 6 g twice daily (total of 12 g)
for 8–16-year-old participants will be given to both study
groups with written and oral instructions on use of the
trial medications.
Selection and withdrawal of participants
Participants will be recruited through advertisements in
local papers, school newsletters, posters, via the internet
and through referrals from general practitioners (GPs)
or dermatologists. Trial information flyers will be placed
in offices of GPs or dermatologists who agree to refer
patients to the trial. Contact details of the potential par-
ticipants who express interest in the trial will be re-
corded. The participant information and consent form
with information about the trial, including the purpose
of the trial, details of the intervention, and potential ad-
verse reactions, will be given to potential participants.
Potential participants will be interviewed to assess their
eligibility against the inclusion and exclusion criteria to
select suitable participants for the trial (screening and
run-in period).
Selection criteria
The U.K. Working Party’s diagnostic criteria and the
Nottingham Eczema Severity Score (NESS) will be
adopted as inclusion criteria for this trial [15–17]. Eli-
gible participants will be boys or girls aged 6–16 years
with a history of skin pruritus within the previous 12
months plus three or more of the following: (1) onset
under the age of 2 years, (2) history of flexural involve-
ment, (3) history of generally dry skin, (4) personal his-
tory of other atopic disease such as asthma or (5) visible
flexural dermatitis. Further, eligible participants will have
a total NESS score ≥9 (moderate to severe) at baseline
and will have provided written informed consent.
Those who used corticosteroids, other immunosup-
pressives or any preparation of oral herbal medicines for
treatment of AE in the past 30 days or who have been
diagnosed with scabies, allergic contact dermatitis, seb-
orrhoeic dermatitis or psoriasis will be excluded. Those
who have severe medical conditions, such as cardiovas-
cular, liver or renal dysfunction, and/or a history of lac-
tose intolerance will not be included.
Withdrawal, dropout and discontinuation
Participants are free to withdraw at any time during the
trial. Participants who wish to withdraw will be offered
the option to cease trial medication but continue attend-
ing scheduled visits for outcome measurement. Partici-
pants who withdraw will be followed to investigate the
reason for withdrawal. Participants may be advised to
discontinue the treatment if there is a product-related
adverse event of a serious nature or if the participantwas not compliant with the study requirements (e.g., use
of oral corticosteroids during the treatment period).
Topical corticosteroid use is allowed for those participants
who were using topical corticosteroids before trial partici-
pation and whose skin conditions worsen during the trial
treatment period. These concomitant medications will be
documented. Discontinuers will not be replaced by new
participants. Intention-to-treat analysis will be performed
on missing data from discontinuers with the last observa-
tion carried forward method.
Sample size
Calculation of the sample size of this trial was based on
the effect size of the primary outcome, Eczema Area and
Severity Index (EASI) score, reported in a previous pub-
lished study [18]. The means and standard deviations
(SDs) of the EASI scores were 7.4 ± 3.3 and 9.6 ± 4.1 for
the active treatment and control groups, respectively. To
achieve 90 % power (β = 0.10), significance level of 0.05
(α) in a two-tailed test, calculated by using G*Power
3.1.2 (http://www.gpower.hhu.de/en.html), 62 partici-
pants, based on an estimated 10 % dropout rate, are
needed for each group. That makes a total of 124 for the
main trial. A pilot study with 30 participants (15 per
group) conducted in RMIT University will provide pre-
liminary data on the clinical efficacy of PTQX based on
EASI score and will allow us to monitor for adverse
events. The mean and SD of EASI score from the pilot
study will be used for recalculation of the sample size
for the main trial.
Screening and run-in, baseline, treatment periods and
endpoint
Preliminary screening assessments will be conducted dur-
ing the 2 weeks of the run-in period (weeks −2 and −1).
Only those participants who have met the inclusion and
exclusion criteria will be randomised. EASI score and
other baseline outcome assessments will be measured.
The treatment period will involve oral ingestion of the
trial medications twice daily for 12 weeks. The trial medi-
cations will be supplied to participants at visit 1 (week 0),
visit 2 (week 4) and visit 3 (week 8). The endpoint is set at
visit 4 (week 12) of the trial period.
Outcome measures
Current recommendations for outcome measurement in
RCTs of AE include clinical signs and symptoms, long-
term control of flares and health-related QoL [19]. This
trial will adopt these recommendations for its outcome
measures. The primary outcome measure is change in
clinical signs severity based on EASI score. Secondary
outcome measures include change in symptoms using
the Patient-Oriented Eczema Measure (POEM) [20],
health-related QoL using the Children’s Dermatology
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medicines (number of days used and total dosage for
corticosteroids) and adverse events and safety (pathology
tests).
The EASI, POEM, CDLQI, concomitant medications
and adverse events will be recorded at visit 1 (week 0),
visit 2 (week 4), visit 3 (week 8), visit 4 (week 12) and
visit 5 (week 16). Pathology tests (full blood examination
with eosinophil count and immunoglobulin E, liver and
renal function tests) will be performed by a qualified
phlebotomist at the screening (week −2) and at the sec-
ond (week 4) and fourth (week 12) visits. Medical advice
from a medical officer will be sought for any serious ad-
verse events or for any serious aggravation of the exist-
ing skin condition or abnormal pathology results during
the trial period.
Any adverse events will be managed in compliance
with the guidelines of the Note for Guidance on Clinical
Safety Data Management: Definitions and Standards
for Expedited Reporting (CPMP/ICH/377/95) issued by
TGA [22]. A serious adverse event will be reported to
the RMIT HREC within 24 hours and then to the TGA
within 7–15 days. Table 1 summarises the schedule of
the trial and outlines the time points of outcome mea-
sures of the trial.
Statistical analysis
Data will be analysed by an independent statistician
using IBM SPSS version 22 software (IBM, Armonk, NY,
USA). Comparison of means of continuous variables
(i.e., EASI, POEM and CDLQI scores) will be expressedTable 1 Schedule of the trial
Items Screening/run-in period V
Week of the trial −2/−1 0
Demographic information-taking +
Informed consent form (PICF) +
General medical history-taking +
Severity of AE for inclusion and exclusion of
the participants (NESS)
+
Blood tests +
Clinical sign of AE (EASI) +
Symptoms (POEM) +
QoL score (CDLQI) +
Distributions of treatment or placebo products +
Daily medical record + +
Monitor of adverse event +
Compliance check +
Survey of participation
Abbreviations: AE atopic eczema, CDLQI Children’s Dermatology Life Quality Index, E
PICF participant information and consent form, POEM Patient-Oriented Eczema Meaas differences in means with 95 % confidence intervals
(CIs). One-way analysis of variance will be used for
normally distributed data, and nonparametric tests will
be used for skewed distribution data. χ2 or Fisher’s
exact tests will be performed for comparison of dichot-
omised data, and dichotomous data will be expressed as
risk ratios with 95 % CIs. All comparisons will be two-
tailed, with p values <0.05 considered to be statistically
significant.
Discussion
Determination of the trial timeline is one of the chal-
lenges of the trial design. It depends on many factors,
such as how long the effect of the intervention may last,
costs of the trial and tolerability by and compliance of
the participants. The trial duration of 16 weeks has been
determined after consideration of these issues. This
protocol was developed according to the guidelines of
Australian Clinical Trial Handbook [23] and follows the
nine CONSORT checklist items for RCTs of herbal medi-
cines [24]. Key elements for conducting a high-quality
RCT, such as randomisation, sequence generation, allo-
cation concealment, blinding methods, proper sample
size, compliance with protocol, determination of base-
line and endpoint and adequate outcome measures have
been addressed.
Trial status
Participant recruitment commenced on 31 March 2015.
It is anticipated that the trial will be completed in
February 2016.isit 1 (baseline) Visit 2 Visit 3 Visit 4 (endpoint) Visit 5 (follow-up)
4 8 12 16
+ +
+ + + +
+ + + +
+ + + +
+ +
+ + + +
+ + + +
+ + + +
+
ASI Eczema Area and Severity Index, NESS Nottingham Eczema Severity Score,
sure, QoL quality of life
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